Filtered By:
Source: The Lancet
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 200 results found since Jan 2013.
Thrombolysis in acute stroke – Authors' reply
Publication date: 11–17 April 2015 Source:The Lancet, Volume 385, Issue 9976 Author(s): Jonathan Emberson , Kennedy R Lees , Patrick Lyden , Colin Baigent , Peter Sandercock , Werner Hacke
Source: The Lancet - April 10, 2015 Category: Journals (General) Source Type: research
Reversible right heart failure after medullary stroke
Publication date: 4–10 April 2015 Source:The Lancet, Volume 385, Issue 9975 Author(s): Han-Gil Jeong , Dae Lim Koo , Hyunwoo Nam , Hyung-Min Kwon
Source: The Lancet - April 3, 2015 Category: Journals (General) Source Type: research
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial
Publication date: Available online 16 March 2015 Source:The Lancet Author(s): Marco Valgimigli , Andrea Gagnor , Paolo Calabró , Enrico Frigoli , Sergio Leonardi , Tiziana Zaro , Paolo Rubartelli , Carlo Briguori , Giuseppe Andò , Alessandra Repetto , Ugo Limbruno , Bernardo Cortese , Paolo Sganzerla , Alessandro Lupi , Mario Galli , Salvatore Colangelo , Salvatore Ierna , Arturo Ausiello , Patrizia Presbitero , Gennaro Sardella , Ferdinando Varbella , Giovanni Esposito , Andrea Santarelli , Simone Tresoldi , Marco Nazzaro , Antonio Zingarelli , Nicoletta de Cesare , Stefano Rigattieri , Paolo Tosi , Cataldo Palmieri ,...
Source: The Lancet - March 17, 2015 Category: Journals (General) Source Type: research
Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs
Publication date: Available online 14 March 2015 Source:The Lancet Author(s): Freek W A Verheugt , Christopher B Granger In patients with non-valvular atrial fibrillation, oral anticoagulation with vitamin K antagonists reduces the risk of stroke by more than 60%. But vitamin K antagonists have limitations, including causing serious bleeding such as intracranial haemorrhage and the need for anticoagulation monitoring. In part related to these limitations, they are used in only about half of patients who should be treated according to guideline recommendations. In the past decade, oral agents have been developed that dire...
Source: The Lancet - March 14, 2015 Category: Journals (General) Source Type: research
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Publication date: Available online 11 March 2015 Source:The Lancet Author(s): Christian T Ruff , Robert P Giugliano , Eugene Braunwald , David A Morrow , Sabina A Murphy , Julia F Kuder , Naveen Deenadayalu , Petr Jarolim , Joshua Betcher , Minggao Shi , Karen Brown , Indravadan Patel , Michele Mercuri , Elliott M Antman Background New oral anticoagulants for stroke prevention in atrial fibrillation were developed to be given in fixed doses without the need for the routine monitoring that has hindered usage and acceptance of vitamin K antagonists. A concern has emerged, however, that measurement of drug concentration or ...
Source: The Lancet - March 12, 2015 Category: Journals (General) Source Type: research
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
This study is registered with ClinicalTrials.gov, number NCT00968708. Findings 5380 patients were assigned to alogliptin (n=2701) or placebo (n=2679) and followed up for a median of 533 days (IQR 280–751). The exploratory extended MACE endpoint was seen in 433 (16·0%) patients assigned to alogliptin and in 441 (16·5%) assigned to placebo (hazard ratio [HR] 0·98, 95% CI 0·86–1·12). Hospital admission for heart failure was the first event in 85 (3·1%) patients taking alogliptin compared with 79 (2·9%) taking placebo (HR 1·07, 95% CI 0·79–1·46). Alogliptin had no effect on composite events of cardiovascular d...
Source: The Lancet - March 12, 2015 Category: Journals (General) Source Type: research
Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials
Publication date: 7–13 March 2015 Source:The Lancet, Volume 385, Issue 9971 Background The cardiovascular benefits of blood pressure lowering in obese people compared with people of normal weight might depend on choice of drug. We compared the effects of blood pressure-lowering regimens on cardiovascular risk in groups of patients categorised by baseline body-mass index (BMI). Methods We used individual patient data from trials included in the Blood Pressure Lowering Treatment Trialists' Collaboration to compare the effects of different classes of blood pressure-lowering regimens for the primary outcome of total major c...
Source: The Lancet - March 6, 2015 Category: Journals (General) Source Type: research
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
Publication date: Available online 6 March 2015 Source:The Lancet Author(s): Jeffrey B Washam , Susanna R Stevens , Yuliya Lokhnygina , Jonathan L Halperin , Günter Breithardt , Daniel E Singer , Kenneth W Mahaffey , Graeme J Hankey , Scott D Berkowitz , Christopher C Nessel , Keith A A Fox , Robert M Califf , Jonathan P Piccini , Manesh R Patel Background Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Com...
Source: The Lancet - March 6, 2015 Category: Journals (General) Source Type: research
Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE)
We examined safety with two, 30 day, adverse event outcome clusters. The trial is registered with ClinicalTrials.gov, number NCT00800384. Findings Between Jan 13, 2009, and April 4, 2011, of 2500 eligible patients, 1253 were randomly assigned to defibrillation testing and 1247 to no-testing, and followed up for a mean of 3·1 years (SD 1·0). The primary outcome of arrhythmic death or failed appropriate shock occurred in fewer patients (90 [7% per year]) in the no-testing group than patients who did receive it (104 [8% per year]; HR 0·86, 95% CI 0·65–1·14; pnon-inferiority <0·0001). The first safety composite...
Source: The Lancet - February 23, 2015 Category: Journals (General) Source Type: research
Blood pressure in acute stroke: which questions remain?
Publication date: 14–20 February 2015 Source:The Lancet, Volume 385, Issue 9968 Author(s): Peter M Rothwell
Source: The Lancet - February 13, 2015 Category: Journals (General) Source Type: research
Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial
This study is registered, number ISRCTN99414122. Findings Between July 20, 2001, and Oct 14, 2013, we enrolled 4011 patients. Mean blood pressure was 167 (SD 19) mm Hg/90 (13) mm Hg at baseline (median 26 h [16–37] after stroke onset), and was significantly reduced on day 1 in 2000 patients allocated to glyceryl trinitrate compared with 2011 controls (difference −7·0 [95% CI −8·5 to −5·6] mm Hg/–3·5 [–4·4 to −2·6] mm Hg; both p<0·0001), and on day 7 in 1053 patients allocated to continue antihypertensive drugs compared with 1044 patients randomised to stop them (difference −9·5 [95% CI −11...
Source: The Lancet - February 13, 2015 Category: Journals (General) Source Type: research
Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial
This study is registered, number ISRCTN25337470. Findings 1713 patients were assigned to stenting (n=855) or endarterectomy (n=858) and followed up for a median of 4·2 years (IQR 3·0–5·2, maximum 10·0). Three patients withdrew immediately and, therefore, the ITT population comprised 1710 patients. The number of fatal or disabling strokes (52 vs 49) and cumulative 5-year risk did not differ significantly between the stenting and endarterectomy groups (6·4% vs 6·5%; hazard ratio [HR] 1·06, 95% CI 0·72–1·57, p=0·77). Any stroke was more frequent in the stenting group than in the endarterectomy group (119 vs 72 ...
Source: The Lancet - February 10, 2015 Category: Journals (General) Source Type: research
The burden of disease in older people and implications for health policy and practice
Publication date: 7–13 February 2015 Source:The Lancet, Volume 385, Issue 9967 Author(s): Martin J Prince , Fan Wu , Yanfei Guo , Luis M Gutierrez Robledo , Martin O'Donnell , Richard Sullivan , Salim Yusuf 23% of the total global burden of disease is attributable to disorders in people aged 60 years and older. Although the proportion of the burden arising from older people (≥60 years) is highest in high-income regions, disability-adjusted life years (DALYs) per head are 40% higher in low-income and middle-income regions, accounted for by the increased burden per head of population arising from cardiovascular disease...
Source: The Lancet - February 10, 2015 Category: Journals (General) Source Type: research
The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial
Publication date: Available online 20 January 2015 Source:The Lancet Author(s): Willeke F Westendorp , Jan-Dirk Vermeij , Elles Zock , Imke J Hooijenga , Nyika D Kruyt , Hans J L W Bosboom , Vincent I H Kwa , Martijn Weisfelt , Michel J M Remmers , Robert ten Houten , A H C M (Tobien) Schreuder , Sarah E Vermeer , Ewout J van Dijk , Diederik W J Dippel , Marcel G W Dijkgraaf , Lodewijk Spanjaard , Marinus Vermeulen , Tom van der Poll , Jan M Prins , Frederique H Vermeij , Yvo B W E M Roos , Ruud P Kleyweg , Henk Kerkhoff , Matthijs C Brouwer , Aeilko H Zwinderman , Diederik van de Beek , Paul J Nederkoorn Background In a...
Source: The Lancet - January 21, 2015 Category: Journals (General) Source Type: research
Preventive antibiotic therapy in stroke: PASSed away?
Publication date: Available online 20 January 2015 Source:The Lancet Author(s): Andreas Meisel
Source: The Lancet - January 21, 2015 Category: Journals (General) Source Type: research
